Rituximab, bendamustine and cytarabine (R‐BAC) in patients with relapsed‐refractory aggressive B‐ and T‐cell lymphoma. (June 2017) - Tisi, M.C.; Paolini, R.; Piazza, F.; Ravelli, E.; Carli, G.; Perbellini, O.; Ruggeri, M.; Visco, C.